• 1
    Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S on behalf of the International Prophylaxis Study Group (IPSG) Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 210.
  • 2
    Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range of 3–74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009; 65: 98998.
  • 3
    Björkman S, Blanchette VS, Fischer K, Oh M, Spotts G, Schroth P, Fritsch S, Patrone L, Ewenstein BW, Collins PW. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost 2010; 8: 7306.
  • 4
    Lee M, Morfini M, Negrier C, Chamouard V. The pharmacokinetics of coagulation factors. Haemophilia 2006; 12(Suppl. 3): 17.
  • 5
    Sheiner LB, Beal S, Rosenberg B, Marathe VV. Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979; 26: 294305.
  • 6
    Ruffo S, Messori A, Grasela TH, Longo G, Donati-Cori G, Matucci M, Morfini M, Tendi E. A calculator program for clinical application of the Bayesian method of predicting plasma drug levels. Comput Programs Biomed 1985; 19: 16777.
  • 7
    Morfini M, Grasela TH, Longo G, Matucci M, Messori A, Vannini S, Rossi-Ferrini PL. Comparison of two pharmacokinetic techniques for individualizing factor VIII dosage in haemophilia patients. Haematologica 1985; 70: 4546.
  • 8
    Messori A, Longo G, Matucci M, Morfini M, Rossi Ferrini PL. Clinical pharmacokinetics of factor VIII in patients with classic haemophilia. Clin Pharmacokinet 1987; 13: 36580.
  • 9
    Björkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 2003; 9(Suppl. 1): 10110.
  • 10
    Bolon-Larger M, Chamouard V, Bressolle F, Boulieu R. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A. Ther Drug Monit 2007; 29: 206.
  • 11
    Björkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia 2010; 16: 597605.
  • 12
    Björkman S. Evaluation of the TCIWorks Bayesian computer program for estimation of individual pharmacokinetics of FVIII. Haemophilia 2011; 17: e23940.
  • 13
    Collins PW, Blanchette VS, Fischer K, Björkman S, Oh M, Fritsch S, Schroth P, Spotts G, Astermark J, Ewenstein B. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 41320.
  • 14
    Björkman S, Carlsson M, Berntorp E, Stenberg P. Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies. Clin Pharmacokinet 1992; 22: 38595.
  • 15
    Stass H. Determination of minimal sampling time points for reliable pharmacokinetic evaluation of recombinant factor VIII – an exploratory population pharmacokinetic analysis in paediatric patients suffering from severe haemophilia. Haemophilia 2006; 12(Suppl. 4): 505.
  • 16
    Karafoulidou A, Suarez E, Anastasopoulou I, Katsarou O, Kuoramba A, Kotsi P, Zografidis A, Lukas JC. Population pharmacokinetics of recombinant factor VIII:C (ReFacto®) in adult HIV-negative and HIV-positive haemophilia patients. Eur J Clin Pharmacol 2009; 65: 112130.
  • 17
    Björkman S, Oh M, Spotts G, Schroth P, Fritsch S, Ewenstein BM, Casey K, Fischer K, Blanchette VS, Collins PW. Population pharmacokinetics of recombinant factor VIII – the relationships of pharmacokinetics to age and body weight. Blood 2012; 119: 61218.